Life Sciences Transplant Care Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Transplant Care Solutions
1.1 - About Life Sciences Transplant Care Solutions sector
Companies in the Life Sciences Transplant Care Solutions category develop diagnostics, preservation technologies, and software that support organ and tissue transplantation workflows end to end. They enable precise donor‑recipient matching, screen donors for infectious risks, extend organ viability through advanced perfusion, and orchestrate logistics and compliance. Customers rely on these offerings to streamline waitlist management, coordinate retrieval and transport, and improve graft outcomes across transplant programs.
Typical offerings include HLA genotyping platforms and virtual crossmatch software to optimize compatibility, donor screening assays for infectious disease and serology, and organ preservation technologies such as hypothermic and normothermic machine perfusion. Vendors also provide transplant program management tools integrating OPTN/UNOS data, waitlist and OR scheduling, chain‑of‑custody tracking with RFID and telemetry, cold‑chain logistics coordination, and analytics that monitor rejection risk with cell‑free DNA and guide immunosuppression titration.
Primary customers include transplant centers within hospital systems, organ procurement organizations, and histocompatibility laboratories. These solutions help teams accelerate donor identification and matching, extend preservation windows to reduce discards, increase graft survival through better risk stratification, and strengthen regulatory compliance and chain-of-custody documentation. Operationally, buyers achieve faster coordination across retrieval, transport, and surgery, improving throughput and lowering avoidable costs per transplant.
2. Buyers in the Life Sciences Transplant Care Solutions sector
2.1 Top strategic acquirers of Life Sciences Transplant Care Solutions companies
CareDx
- Description: Provider of non-invasive, genomics-based diagnostic and surveillance solutions that measure donor-derived cell-free DNA and gene expression to manage organ transplant patients, offering blood tests and HLA typing tools to detect allograft injury, monitor rejection risk and improve transplant outcomes.
- Key Products:
- AlloSure: Non-invasive NGS blood test quantifies donor-derived cell-free DNA to detect kidney allograft injury and active rejection with higher accuracy than serum creatinine
- AlloMap: Gene-expression blood test analyzes 20 genes to identify heart transplant patients with low risk of moderate/severe acute cellular rejection, guiding biopsy decisions
- AlloSure Lung: Surveillance assay for lung transplants prognoses chronic lung allograft dysfunction, detects acute cellular rejection onset and monitors treatment response
- HeartCare: Integrated AlloSure and AlloMap Heart monitoring program enabling early heart transplant surveillance, delivering comparable five-year outcomes while significantly reducing redundant biopsies.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Transplant Care Solutions sector
M&A buyer group 1: Organ Preservation Systems
TransMedics
- Type: N/A
- Employees: ●●●●●
- Description: Provider of medical technology and logistics solutions for organ transplantation, offering its FDA-approved Organ Care System (OCS) platforms and nationwide National OCS Program to keep donor organs functioning, assess viability in real time, and streamline retrieval and transport, thereby expanding access to usable organs and increasing transplant volumes.
- Key Products:
- OCS Heart: OCS Heart preserves and transports donor hearts in a warm, functioning state, maintaining viability and perfusion to increase successful heart transplant opportunities and outcomes
- OCS Lung: OCS Lung keeps donor lungs alive and functioning while enabling clinical assessment during transport, improving graft quality and post-transplant results for recipients
- OCS Liver: OCS Liver provides normothermic perfusion and monitoring of donor livers during transit, reducing ischemic injury and enhancing transplant success and organ utilization
- Services and Support: TransMedics supplies training, technical assistance and logistics coordination that integrates OCS devices into hospital workflows, ensuring reliable operation, compliance and streamlined transplant procedures
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Transplant Care Solutions sector
3.1 - Buyout funds in the Life Sciences Transplant Care Solutions sector
2.2 - Strategic buyer groups for Life Sciences Transplant Care Solutions sector
4 - Top valuation comps for Life Sciences Transplant Care Solutions companies
4.2 - Public trading comparable groups for Life Sciences Transplant Care Solutions sector
Valuation benchmark group 1: Molecular Diagnostics and Genomics Tools Companies
Agilent Technologies
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of design, manufacturing, and marketing of measurement instruments primarily for communications, electronics, life sciences, and chemistry sectors.
- Key Products:
- Gas Chromatographs: Instruments for separating chemical compounds into individual components for analysis
- Liquid Chromatographs: Tools for separating, identifying, and quantifying components in a liquid sample
- Mass Spectrometers: Analyzers for identifying chemical structures and determining molecule weights
- Lab Automation Systems: Robots and software for enhancing efficiency in laboratory workflows
- Genomics Solutions: Products for gene sequencing, expression analysis, and mutation detection.